ArticleBMC cancer2019
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review.Current oncology (Toronto, Ont.) · 2022Pooled it
- Exploring the psychological impact and healthcare experiences of patients living withBMJ open · 2026Article
- Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study.British journal of haematology · 2026Article
- Article
- Psychosocial Impact Following Acute Hospitalization Among Patients With Hematologic Malignancies and Their Family Caregivers: A Content Analysis.Psycho-oncology · 2026Article
- Shared Decision-Making in Treatment Selection in Multiple Myeloma in Spain: The PRISMMA Study.European journal of haematology · 2026Article
- iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study.Patient preference and adherence · 2026Article
- Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.Future oncology (London, England) · 2025Article
- Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies.Patient preference and adherence · 2025Article
- Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States.Patient preference and adherence · 2025Article
- The Role of CELMoD Agents in Multiple Myeloma.OncoTargets and therapy · 2025Review
- Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway.Heliyon · 2024Article
- Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe.Patient preference and adherence · 2024Article
- Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group.Frontiers in health services · 2024Article
- Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study.BMC cancer · 2023Article
- The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.Cancer reports (Hoboken, N.J.) · 2022Article
- Review
- Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMultiple myeloma is a haematological malignancy characterized by significant morbidity and mortality. This study sought to develop an in-depth understanding of patients' lived experiences of relapsed or refractory multiple myeloma (RRMM) and its treatment, and to identify which features of treatment were most important to them.
methodsQualitative interviews and focus groups (FGs) were conducted with 32 people living with RRMM across Canada. In Phase 1, interviews focused on participants' accounts of their experiences with the disease and its treatment and laid the groundwork for the FGs (Phase 2). The FGs developed a deeper understanding of patients' treatment priorities. Interview and FG transcripts were coded for emergent themes and patterns.
resultsThe interviews identified important side effects that had significant impacts on patients' lives, including physical, cognitive, and psychological/emotional side effects. Participants also identified specific treatment features (attributes) that were important to them. These were compiled into a list and used in the FGs to understand patients' priorities. Higher prioritized attributes were: life expectancy, physical and cognitive side effects, and financial impact. Mode of administration, treatment intervals, psychological side effects, and sleep/mood effects were identified as lower priorities.
conclusionsRRMM and its treatments impact importantly on patients' quality-of-life across a range of domains. Patients prioritized treatment features that could enhance life expectancy, minimize side effects and offset financial burdens. IMPLICATIONS FOR CANCER SURVIVORS: A clear articulation of patient priorities can contribute to efforts to design treatment with patients' concerns in mind, thereby promoting a more patient-centered approach to care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.